Navigation Links
PeriGen, Inc. Forms Strategic Alliance with Willis Healthcare to Improve Quality of Care in OB
Date:2/9/2011

PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- PeriGen, Inc., the only OB-specific risk reduction company to provide solutions which generate immediate quantifiable clinical and financial value, today announced the formation of a strategic alliance with Willis Group Holdings (NYSE: WSH), a leading global insurance broker and one of the world's largest professional services firms specializing in risk management. According to the terms of the alliance, Willis will offer PeriGen's unique OB-specific products and services to its clients, in an effort to reduce risk and associated medical malpractice costs by improving the quality of care delivered.

"As medical malpractice insurance brokers and experts in risk management, we are very aware of the cost of errors in Obstetrics," said Mary S. Botkin, Managing Director, Willis National Health Care. "Obstetrics ranks first among all specialties for the number of claims reported and for the total amount of indemnity paid. PeriGen's solutions address the root causes behind preventable medical errors, alerting clinicians to potentially significant contraindications and identifying safer courses of care. At Willis, we recognize the unique value of PeriGen's products and services in preventing errors and improving clinical outcomes, and we are proud to offer PeriGen's solutions to our clients."

PeriGen's integrated fetal monitoring, documentation, and clinical decision support systems help over 15,000 clinicians provide safer care to their patients. Additionally, PeriGen helps hospitals to improve clinical and financial outcomes through the design and implementation of risk management and patient safety initiatives, clinical quality improvement programs, perinatal training courses, business improvement programs, and revenue enhancement strategies. PeriGen's solutions are complemented by a full suite of patented, proprietary technologies, which represent the next generation of clinical decision support tools for Obstetrics. Providing real-time, interactive guidance at the patient's bedside, PeriGen's fetal monitor and OB patient record facilitate the delivery of consistent, repeatable high-quality care.

"It is common for insurance brokers to anticipate risk, but Willis is unique in its approach to claims prevention," said Donald A. Deieso, Ph.D., Chairman and CEO of PeriGen. "Recognizing that the most effective guard against medical malpractice claims is high-quality, evidence-based care, Willis has chosen to arm its clients with PeriGen's sophisticated risk management and quality improvement tools. We are proud to collaborate with an insurance broker of Willis' caliber and foresight, and we are honored to have been selected to share our offerings with Willis' client base."

About PeriGen, Inc. PeriGen is a technology-enabled professional services company specializing in risk reduction and clinical quality improvement in Obstetrics and is the only OB-specific risk reduction company to provide solutions which generate immediate, quantifiable and clinical value. Singularly focused on reducing risk and improving financial performance, PeriGen's advanced clinical decision support and fetal monitoring solutions are installed in over 100 hospitals across North America. A pioneer in advanced clinical decision support, PeriGen provides innovative solutions and a full suite of complementary professional and consulting services that reduce risk and improve clinical outcomes. PeriGen is a US corporation headquartered in Princeton, New Jersey, with offices in Canada and Israel. For more information, please visit us at www.perigen.com.

About WillisWillis Group Holdings plc is a leading global insurance broker, developing and delivering professional insurance, reinsurance, risk management, financial and human resource consulting and actuarial services to corporations, public entities and institutions around the world. Willis has more than 400 offices in nearly 120 countries, with a global team of approximately 17,000 employees serving clients in virtually every part of the world. Additional information on Willis may be found at www.willis.com.Contacts: Sandra Taylor, Ph.D.Chief Marketing Officer, PeriGen (609) 228-8346Sandra.Taylor@PeriGen.com Colleen McCarthyDirector of Communications, Willis(212) 915-8307 Colleen.McCarthy@Willis.com
'/>"/>

SOURCE PeriGen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Allegheny General Hospital Performs First Liver Transplant
2. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
3. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
4. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
7. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
8. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
9. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. Huntington Hospital Surgeon Performs First Single Port Resection on Colorectal Cancer Patient in CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NEW YORK , May 2, 2016 ... the EMR (Electronic Medical Records) market in a recent ... International sales, vendor switches, Increased physician usage, a growing market ... trends were noted in Kalorama,s report EMR ... The report marks Kalorama,s seventh complete study of the ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic ... treatments to both new and existing patients. Cosmetic dentistry allows patients to improve the ... have healthy smiles with some minor or more serious cosmetic flaws. These specials allow ...
(Date:5/3/2016)... ... May 03, 2016 , ... Celestix ... announced the new SecureAccess feature for its CelestixEdge solution. CelestixEdge is the ... enable organizations to get the DirectAccess user experience on unsupported DirectAccess clients ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... helps healthcare organizations, especially medium and small physician practices, to better grasp and ... unique step-by-step approach that guides practices on a well-defined, expert-created path to compliance. ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK Products, Inc. (RNK) ... software that enables the stethoscope stream to go over the video conferencing audio ... flagship PCP-USB stethoscope. , Remote auscultation involves two software elements on the PC: ...
(Date:5/2/2016)... ... May 02, 2016 , ... The ... Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research ... issue representing international (non-US) based authors, the third volume of PXJ continues to ...
Breaking Medicine News(10 mins):